COMPASS Pathways plc (CMPS) Bundle
A Brief History of COMPASS Pathways
COMPASS Pathways plc is a clinical-stage biotechnology company focused on developing innovative therapies for mental health conditions. Founded in 2016, the company aims to revolutionize mental health treatment through its proprietary psilocybin therapy, COMP360.
Initial Public Offering and Growth
COMPASS Pathways went public in September 2020, raising approximately $146 million in its initial public offering (IPO). The IPO was well-received, reflecting strong investor interest in innovative mental health solutions. The company’s shares were listed on the NASDAQ under the ticker symbol "CMPS."
Financial Performance and Key Developments
As of September 30, 2024, COMPASS Pathways reported total assets of $247.3 million, down from $276.0 million at the end of 2023. The company incurred a net loss of $111.8 million for the nine months ended September 30, 2024, compared to a net loss of $85.9 million for the same period in 2023. This loss primarily stemmed from ongoing research and development expenses related to their COMP360 psilocybin therapy program.
| Financial Metric | 2024 (Nine Months) | 2023 (Nine Months) |
|---|---|---|
| Net Loss | $111.8 million | $85.9 million |
| Research and Development Expenses | $86.9 million | $60.4 million |
| Cash and Cash Equivalents | $207.0 million | $248.4 million |
| Accumulated Deficit | $491.4 million | $379.6 million |
| Total Assets | $247.3 million | $276.0 million |
Research and Development Focus
The primary focus of COMPASS Pathways is advancing their Phase 3 clinical trials for the COMP360 psilocybin treatment, targeting treatment-resistant depression (TRD). The ongoing studies aim to provide robust data to support regulatory submissions in the future. Research and development expenses have increased substantially, reflecting the company's commitment to clinical trials and regulatory compliance.
Funding and Capital Structure
COMPASS Pathways has funded its operations through various means, including capital raised from its IPO and subsequent equity offerings. As of September 30, 2024, the company had raised approximately $54.8 million through its At-The-Market (ATM) facility since its inception. The company also entered into a loan agreement with Hercules Capital, with total borrowings of $30 million as of the same date.
| Funding Source | Amount Raised |
|---|---|
| IPO | $146 million |
| ATM Facility | $54.8 million |
| Hercules Capital Loan | $30 million |
Market Position and Future Outlook
COMPASS Pathways is positioned as a leader in the emerging field of psychedelic therapies for mental health. The company continues to explore potential partnerships and collaborations to enhance its market footprint and expedite the development of its therapeutic candidates. The future outlook remains focused on advancing clinical trials and achieving regulatory approvals for its lead product candidate.
As of September 30, 2024, the company had cash and cash equivalents sufficient to fund operations into 2026, indicating a solid financial position to support ongoing projects. However, the need for additional funding remains crucial as the company progresses through its clinical trials and prepares for commercialization.
A Who Owns COMPASS Pathways plc (CMPS)
Ownership Structure
As of September 30, 2024, the significant shareholders of COMPASS Pathways plc include executive officers, directors, and certain major shareholders, who collectively own approximately 23.6% of the ordinary shares and American Depository Shares (ADSs). This concentration of ownership can significantly influence corporate decisions and shareholder meetings.
Major Shareholders
| Shareholder Type | Ownership Percentage | Number of Shares Owned |
|---|---|---|
| Executive Officers | Varies | Not disclosed |
| Directors | Varies | Not disclosed |
| Institutional Investors | Approx. 20% | Not disclosed |
| Retail Investors | Approx. 56.4% | Not disclosed |
Institutional Ownership
Institutional investors play a crucial role in the ownership structure of COMPASS Pathways. They hold a significant portion of the shares, which is essential for providing stability and potential strategic direction. As of the latest reports, approximately 20% of the shares are held by institutional investors.
Recent Share Issuances
COMPASS Pathways has engaged in several share issuances to raise capital. Notably, through the At-The-Market (ATM) offering program, the company has sold 5,491,836 ADSs, generating approximately $54.8 million in net proceeds. Additionally, the company issued 16,076,750 ADSs under a private investment in public equity (PIPE) agreement.
Warrants and Options
As part of its financing strategy, COMPASS Pathways has also issued warrants. The PIPE agreement includes warrants for up to 16,076,750 ADSs, with an exercise price of $9.93 per ADS, which are exercisable beginning in February 2024.
Implications of Ownership Concentration
The concentrated ownership among executive officers and major shareholders may lead to significant influence over corporate governance decisions, including board member appointments and strategic directions. This could also deter unsolicited acquisition proposals.
Financial Overview
As of September 30, 2024, COMPASS Pathways reported total shareholders' equity of $193.0 million and an accumulated deficit of $491.4 million. The company has incurred net losses of $111.8 million for the nine months ended September 30, 2024.
Conclusion on Ownership and Financial Health
The ownership structure of COMPASS Pathways, characterized by a significant presence of institutional investors and concentrated control among executives and directors, shapes the company’s strategic decisions and long-term viability. The ongoing net losses highlight the financial challenges faced in the biotechnology sector as the company continues to develop its investigational treatments.
COMPASS Pathways plc (CMPS) Mission Statement
Mission Overview
COMPASS Pathways plc is a clinical-stage biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The company aims to deliver transformative therapies for treatment-resistant depression (TRD) and other mental health conditions through its investigational COMP360 psilocybin treatment.
Core Values
- Innovation: COMPASS focuses on pioneering research and development initiatives to create groundbreaking therapies.
- Patient-Centricity: The company prioritizes patient needs and strives to enhance their quality of life through effective treatments.
- Collaboration: Building strong partnerships with healthcare providers, researchers, and regulatory bodies is essential for advancing mental health care.
- Integrity: Upholding high ethical standards in research and business practices is fundamental to COMPASS’s operations.
Strategic Goals for 2024
In 2024, COMPASS Pathways aims to:
- Complete Phase 3 clinical trials for COMP360 psilocybin treatment for TRD.
- Enhance its intellectual property portfolio to protect innovations.
- Expand clinical partnerships to facilitate broader access to treatment.
- Increase awareness and education around psilocybin therapy in mental health.
Financial Overview
COMPASS Pathways has encountered significant financial challenges, reflecting its investment in R&D and operational growth. The following table summarizes key financial data as of September 30, 2024:
| Financial Metric | Amount (in thousands USD) |
|---|---|
| Net Loss (Nine Months) | $111,790 |
| Accumulated Deficit | $491,400 |
| Cash and Cash Equivalents | $207,342 |
| Total Assets | $247,338 |
| Total Liabilities | $54,308 |
| Total Shareholders' Equity | $193,030 |
| Research and Development Expenses (Nine Months) | $86,898 |
| General and Administrative Expenses (Nine Months) | $42,893 |
Research and Development Focus
COMPASS is heavily invested in its R&D, primarily focused on the development of the COMP360 psilocybin treatment. The company has reported the following R&D expenses for the three months ended September 30, 2024:
| Expense Type | Amount (in thousands USD) |
|---|---|
| Development Expenses | $22,647 |
| Personnel Expenses | $6,409 |
| Non-cash Share-based Compensation | $2,661 |
| Other Expenses | $1,211 |
| Total R&D Expenses | $32,928 |
Future Funding Requirements
To continue its operations and R&D efforts, COMPASS anticipates needing substantial funding. As of September 30, 2024, the company has outlined potential funding sources:
- Equity offerings through its ATM program, with the capacity to raise up to $150 million.
- Proceeds from PIPE Warrants, estimated at up to $122.4 million if fully exercised.
- Loan agreements, including a term loan with Hercules totaling $30 million.
COMPASS Pathways remains committed to advancing mental health treatments and addressing the unmet needs of patients suffering from TRD and other conditions. The company's ongoing efforts in research, clinical trials, and partnerships are essential for achieving its mission and strategic objectives.
How COMPASS Pathways plc (CMPS) Works
Company Overview
COMPASS Pathways plc is a clinical-stage biotechnology company focused on developing innovative therapies using psychedelics, specifically psilocybin, to treat mental health conditions. As of 2024, the company primarily works on its investigational COMP360 psilocybin treatment for treatment-resistant depression (TRD).
Financial Performance
For the nine months ended September 30, 2024, COMPASS Pathways reported:
- Net loss of $111.8 million
- Operating expenses totaling $129.8 million
- Research and development expenses of $86.9 million
- General and administrative expenses amounting to $42.9 million
In comparison, for the same period in 2023, the net loss was $85.9 million, with operating expenses of $98.5 million, indicating an increase in operating losses year-over-year.
Shareholders' Equity
As of September 30, 2024:
| Category | Amount (in thousands) |
|---|---|
| Ordinary Shares | $699 |
| Additional Paid-In Capital | $700,273 |
| Accumulated Other Comprehensive Loss | $(16,542) |
| Accumulated Deficit | $(491,400) |
| Total Shareholders' Equity | $193,030 |
Cash Flow Summary
For the nine months ended September 30, 2024, the following cash flow details were reported:
| Cash Flow Category | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net Cash Used in Operating Activities | $(77,429) | $(69,594) |
| Net Cash Used in Investing Activities | $0 | $(64) |
| Net Cash Provided by Financing Activities | $63,669 | $173,789 |
| Net (Decrease) Increase in Cash | $(13,296) | $104,988 |
| Ending Cash, Cash Equivalents, and Restricted Cash | $207,342 | $248,369 |
Research and Development
Research and development (R&D) expenses are a significant focus for COMPASS Pathways, particularly for the COMP360 psilocybin therapy. The breakdown of R&D expenses for the nine months ended September 30, 2024, is as follows:
| R&D Expense Category | Amount (in thousands) |
|---|---|
| Development Expenses | $54,628 |
| Personnel Expenses | $19,893 |
| Non-cash Share-Based Compensation | $7,921 |
| Other Expenses | $4,456 |
| Total R&D Expenses | $86,898 |
Debt Obligations
COMPASS Pathways has entered into a Loan Agreement with Hercules Capital, which allows for borrowings of up to $50 million. As of September 30, 2024, the company had drawn down $30 million from this agreement. The interest on the loan is subject to either the prime rate plus 1.50% or a minimum of 9.75% annually.
Market Conditions and Future Outlook
As of September 30, 2024, COMPASS Pathways had cash and cash equivalents of $207 million, which is projected to fund operations into 2026. However, the company has not yet generated revenue and relies heavily on financing through equity offerings and partnerships to sustain its operations and research initiatives.
How COMPASS Pathways plc (CMPS) Makes Money
Business Model Overview
COMPASS Pathways plc is a clinical-stage biotechnology company focused on developing innovative treatments for mental health conditions, particularly treatment-resistant depression (TRD) using its investigational product, COMP360 psilocybin therapy. As of 2024, the company has not generated any revenue from therapeutic candidates and does not expect to do so in the near future. The primary funding sources have included private placements of equity, warrants, and convertible notes since its initial public offering (IPO) in 2020.
Financial Performance
As of September 30, 2024, COMPASS Pathways reported a net loss of $111.8 million for the nine months ended, compared to a net loss of $85.9 million for the same period in 2023. The company has accumulated losses totaling $491.4 million since its inception.
| Financial Metric | 2024 (9 months) | 2023 (9 months) |
|---|---|---|
| Net Loss | $111.8 million | $85.9 million |
| Accumulated Deficit | $491.4 million | N/A |
Operating Expenses
The company's operating expenses for the nine months ended September 30, 2024, were $129.8 million, primarily driven by research and development (R&D) and general administrative costs.
| Expense Category | 2024 (9 months) | 2023 (9 months) |
|---|---|---|
| Research and Development | $86.9 million | $60.4 million |
| General and Administrative | $42.9 million | $38.1 million |
| Total Operating Expenses | $129.8 million | $98.5 million |
Funding Sources
COMPASS Pathways has funded its operations through various means, including:
- Public equity offerings
- Private placements of American Depositary Shares (ADSs)
- Debt financing, including a loan agreement with Hercules Capital
- At-the-market (ATM) offerings
As of September 30, 2024, the company had cash and cash equivalents of $207.0 million, which is projected to fund operations into 2026.
Future Revenue Potential
COMPASS Pathways aims to generate revenue through the commercialization of its investigational COMP360 psilocybin therapy, pending successful completion of clinical trials and regulatory approvals. The company is currently in its Phase 3 trial for TRD and has plans to expand its therapeutic indications to other mental health conditions.
Investment and Development Costs
The anticipated costs associated with the development of COMP360 and other future therapeutic candidates are substantial. Key components include:
- Completion of clinical trials
- Regulatory compliance and filing for approvals
- Manufacturing and scaling production capabilities
- Training healthcare professionals
COMPASS Pathways expects to incur significant costs associated with these activities, which will further increase the company's operating losses in the short to medium term.
| Cash Flow Summary (in thousands) | 2024 (9 months) | 2023 (9 months) |
|---|---|---|
| Net cash used in operating activities | $(77,429) | $(69,594) |
| Net cash used in investing activities | $0 | $(64) |
| Net cash provided by financing activities | $63,669 | $173,789 |
In summary, COMPASS Pathways plc continues to focus on advancing its clinical programs while managing substantial operating losses and relying on external funding to support its operations and growth strategy.
COMPASS Pathways plc (CMPS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Article updated on 8 Nov 2024
Resources:
- COMPASS Pathways plc (CMPS) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of COMPASS Pathways plc (CMPS)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View COMPASS Pathways plc (CMPS)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.